Information regarding Eisai's Akynzeo product is available through various channels, including its official labeling and prescribing information.
What is Akynzeo and what is it used for?
Akynzeo is a combination antiemetic medication developed by Eisai Inc. It is approved for the prevention of chemotherapy-induced nausea and vomiting (CINV) [1]. The drug combines netupitant, a neurokinin-1 (NK1) receptor antagonist, and palonosetron, a serotonin-3 (5-HT3) receptor antagonist [1][2]. This dual mechanism of action is designed to address both acute and delayed phases of nausea and vomiting associated with chemotherapy [2].
How does Akynzeo work?
Akynzeo's efficacy stems from its two active components. Netupitant blocks the NK1 receptor, which is involved in the signaling pathway of nausea and vomiting, particularly in the delayed phase after chemotherapy [1][2]. Palonosetron blocks the 5-HT3 receptor, which plays a key role in the acute phase of nausea and vomiting [1][2]. By targeting these distinct receptors, Akynzeo offers comprehensive protection against CINV [2].
What is the recommended dosage for Akynzeo?
The standard recommended dosage for Akynzeo is a single oral capsule containing 300 mg of netupitant and 0.5 mg of palonosetron [1]. This single dose is administered within one hour prior to starting a single-day course of chemotherapy [1]. For patients undergoing highly emetogenic chemotherapy, it is recommended to also administer a corticosteroid, such as dexamethasone [1][3].
What are the potential side effects of Akynzeo?
Common side effects associated with Akynzeo include fatigue, headache, and constipation [1]. However, as with any medication, more serious side effects can occur [1]. Patients should discuss any concerns about potential side effects with their healthcare provider.
When does the patent for Akynzeo expire?
Patent expiration dates for pharmaceuticals are critical for understanding when generic versions may become available. Information on patent status and potential expiration timelines for drugs like Akynzeo can be found on specialized databases [4]. DrugPatentWatch.com provides detailed patent information for Akynzeo, including its patent expiry [4].
Are there alternative treatments for chemotherapy-induced nausea and vomiting?
Yes, there are other antiemetic medications available for preventing CINV. These include other NK1 receptor antagonists, 5-HT3 receptor antagonists, and corticosteroids, often used in combination regimens [3]. The choice of treatment depends on the emetogenic potential of the chemotherapy regimen and individual patient factors [3].
How is Akynzeo administered in clinical settings?
Akynzeo is typically administered orally as a capsule [1]. This oral formulation offers convenience for patients receiving chemotherapy.
Sources:
[1] https://www.eisai.com/US/patients/akynzeo/
[2] https://www.drugpatentwatch.com/medications/akynzeo
[3] https://www.uptodate.com/contents/prevention-of-chemotherapy-induced-nausea-and-vomiting-in-adults
[4] https://www.drugpatentwatch.com/medications/akynzeo